Clinical Studies

Pompe Disease

ATB200/AT2221: Phase 1/2 Safety Study (ATB200-02 Study)

Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ATB200 Co-administered with Oral AT2221 in Patients with Pompe Disease

Active, not recruiting

Open-label, dose-escalation study of patients 18 to 65 years with a diagnosis of Pompe disease Pompe disease patients to assess if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.

More information: www.clinicaltrials.gov: NCT02675465